PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph G. Zinner; Coleman K. Obasaju; David R. Spigel; Robert W. Weaver; J. Thaddeus Beck; David M. Waterhouse; Manuel R. Modiano; Borys Hrinczenko; Petros G. Nikolinakos; Jingyi Liu; Andrew G. Koustenis; Katherine B. Winfree; Symantha A. Melemed; Susan C. Guba; Waldo I. Ortuzar; Durisala Desaiah; Joseph A. Treat; Ramaswamy Govindan; Helen J. Ross

doi:10.1097/jto.0000000000000366

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000366 ◽

2015 ◽

Vol 10 (1) ◽

pp. 134-142 ◽

Cited By ~ 75

Author(s):

Ralph G. Zinner ◽

Coleman K. Obasaju ◽

David R. Spigel ◽

Robert W. Weaver ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.517 ◽

2020 ◽

Vol 31 ◽

pp. S1428

Author(s):

Y. Shi ◽

L. Wu ◽

X. Yu ◽

P. Xing ◽

J. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Previously Treated

Download Full-text

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.3816/clc.2009.n.035 ◽

2009 ◽

Vol 10 (4) ◽

pp. 252-256 ◽

Cited By ~ 49

Author(s):

Jyoti D. Patel ◽

Philip Bonomi ◽

Mark A. Socinski ◽

Ramaswamy Govindan ◽

Shengyan Hong ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Study Design ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study

The Lancet Oncology ◽

10.1016/s1470-2045(08)70261-4 ◽

2008 ◽

Vol 9 (12) ◽

pp. 1135-1142 ◽

Cited By ~ 55

Author(s):

Kaoru Kubota ◽

Masaaki Kawahara ◽

Mitsumasa Ogawara ◽

Yutaka Nishiwaki ◽

Kiyoshi Komuta ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30641-0 ◽

2021 ◽

Vol 22 (2) ◽

pp. 198-211 ◽

Cited By ~ 2

Author(s):

Luis Paz-Ares ◽

Tudor-Eliade Ciuleanu ◽

Manuel Cobo ◽

Michael Schenker ◽

Bogdan Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70428-7 ◽

2007 ◽

Vol 2007 ◽

pp. 215-216

Author(s):

N.H. Hanna

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Extensive Disease ◽

Phase Iii Study ◽

Oral Topotecan

Download Full-text

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7500 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7500-7500 ◽

Cited By ~ 59

Author(s):

J. Jassem ◽

C. J. Langer ◽

D. D. Karp ◽

T. Mok ◽

R. J. Benner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps8578 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS8578-TPS8578 ◽

Cited By ~ 14

Author(s):

Leora Horn ◽

Martin Reck ◽

Scott N. Gettinger ◽

David R. Spigel ◽

Scott Joseph Antonia ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Platinum Based Chemotherapy

Download Full-text

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/j.1743-7563.2012.01518.x ◽

2012 ◽

Vol 8 (3) ◽

pp. 232-243 ◽

Cited By ~ 21

Author(s):

Yi-Long WU ◽

Da-Tong CHU ◽

Baohui HAN ◽

Xuyi LIU ◽

Li ZHANG ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Mainland China ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label

Download Full-text

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

10.1158/1538-7445.sabcs18-ct074 ◽

2019 ◽

Cited By ~ 3

Author(s):

Solange Peters ◽

Byoung Chul Cho ◽

Niels Reinmuth ◽

Ki Hyeong Lee ◽

Alexander Luft ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Mutational Burden ◽

Tumor Mutational Burden ◽

Phase Iii Study

Download Full-text